Rgenix reports Phase I data for cancer compound RGX-104

Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. RGX-104 increased activated circulating PD-1+ CD8+ T cells by up to 11-fold in 9 of 10 evaluable patients. Additionally, the candidate reduced myeloid-derived suppressor cells by up to 95% and led to dendritic cell activation as measured by PD-L1 induction expression, with an increase of up to 100%.

There was 1 reported dose-limiting toxicity (DLT) of grade 4 reversible neutropenia. The maximum tolerated dose (MTD), a co-primary endpoint, has not been reached. Data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia...